PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Prostate cancer stem cells are a moving target, UCLA researchers say

2013-12-04
(Press-News.org) Contact information: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Prostate cancer stem cells are a moving target, UCLA researchers say UCLA researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies.

Following recent studies showing that prostate cancer originates in basal stem cells, UCLA researchers were surprised to discover that the cancer eventually begins to grow from a different type of cell called a luminal stem cell. The new discovery indicates that the basal stem cells evolve into luminal stem cells as the cancer grows. Existing prostate cancer drugs are designed to seek out and kill the basal stem cells that give rise to the cancer, so the evolution from basal to luminal stem cells creates a "moving target" that renders the drugs less effective over time.

The study, by Andrew Goldstein, Dr. Owen Witte, Tanya Stoyanova and colleagues from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and UCLA's Jonsson Comprehensive Cancer Center, was published online by the Proceedings of the National Academy of Sciences and will appear later in the journal's print edition.

Adult stem cells are tissue-specific cells that regenerate and replace diseased or damaged cells in the body's organs. Cancer starts in basal stem cells in the lining of the prostate gland, the epithelium, and they lose their ability to control their growth. Tumors that start as uncontrolled growth in basal stem cells continue to grow from luminal stem cells, another type of cell in the prostate epithelium.

"People have begun to think about cancers as being driven by stem cells in the same way that many of our adult organs are maintained by dedicated stem cells," Goldstein said. "Based on this new understanding, we are excited about going right to the root of the tumor and targeting those stem cells to eradicate the cancer."

Patients with aggressive prostate cancer are often treated with anti-androgens, drugs that block production of hormones such as testosterone that make the cancer more aggressive. The tumor stem cells that remain after the anti-androgen treatment look different from the basal and luminal cells. This means that for treatments that target specific cell types, researchers need to identify the different cell types that evolve as the disease and its treatment progress.

With the knowledge that prostate cancer stem cells can change their physical appearance, or phenotype, from one type of cell to another, the UCLA researchers are now seeking to understand whether certain elements of the stem cells remain consistent even as they evolve from one cell type to another. This knowledge could help scientists develop drugs that target the evolving cancer stem cells by aiming for the elements that remain unchanged.

### The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 200 members, the stem cell center is committed to a multi-disciplinary, integrated collaboration of scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The center supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed towards future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine, UCLA's Jonsson Comprehensive Cancer Center, the Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science.

For more news, visit the UCLA Newsroom and follow us on Twitter.


ELSE PRESS RELEASES FROM THIS DATE:

Radiographic imaging exposes relationship between obesity and cancer

2013-12-04
Radiographic imaging exposes relationship between obesity and cancer Even with healthy BMI, greater visceral fat may put older men at risk for cancer Researchers at the National Institute for Aging are working to improve understanding about ...

Intense 2-color double X-ray laser pulses: a powerful tool to study ultrafast processes

2013-12-04
Intense 2-color double X-ray laser pulses: a powerful tool to study ultrafast processes A team working at the SACLA X-ray Free-Electron Laser (XFEL) in Japan has succeeded in generating ultra-bright, two-color X-ray laser pulses, for the first time in the hard X-ray region. ...

New study identifies 5 distinct humpback whale populations in North Pacific

2013-12-04
New study identifies 5 distinct humpback whale populations in North Pacific NEWPORT, Ore. – The first comprehensive genetic study of humpback whale populations in the North Pacific Ocean has identified five distinct populations – at the same time a proposal ...

Dads: How important are they?

2013-12-04
Dads: How important are they? New MUHC research highlights the value of fathers in both neurobiology and behavior of offspring This news release is available in French. MONTREAL December 4th, 2013 — Even with today's technology, it still ...

10 times more throughput on optic fibers

2013-12-04
10 times more throughput on optic fibers EPFL scientists have shown how to achieve a dramatic increase in the capacity of optical fibers; Their simple, innovative solution reduces the amount of space required between the pulses of light that ...

Baicalin inhibits neurotoxicity of colistin sulfate effectively

2013-12-04
Baicalin inhibits neurotoxicity of colistin sulfate effectively Baicalin, a type of flavonoid extracted from the dried root of Scutellaria baicalensis georgi, has been shown to effectively inhibit cell apoptosis. Colistin sulfate, a cyclic cationic polypeptide ...

Toll-like receptor 4-mediated apoptosis of hippocampal neurons

2013-12-04
Toll-like receptor 4-mediated apoptosis of hippocampal neurons Toll-like receptor 4 (TLR4) antibody, protein kinase B (AKT) inhibitor, LY 294002, and glycogen synthase kinase 3β (GSK-3β) inhibitor, LiCl, were used by Yu He and colleagues from Nantong University, ...

Parkinson's disease patients following subthalamic nucleus deep brain stimulation: fully understanding of social maladjustment

2013-12-04
Parkinson's disease patients following subthalamic nucleus deep brain stimulation: fully understanding of social maladjustment Subthalamic nucleus deep brain stimulation can significantly improve the motor features of the Parkinson's disease in carefully selected ...

Depression in pregnant mothers may alter the pattern of brain development in their babies

2013-12-04
Depression in pregnant mothers may alter the pattern of brain development in their babies Reports a new study in Biological Psychiatry Philadelphia, PA, December 4, 2013 – Depression is a serious mental illness that has many negative consequences for sufferers. But depression ...

Rapid climate changes, but with a 120 year time lag

2013-12-04
Rapid climate changes, but with a 120 year time lag Regional climate changes can be very rapid. A German-British team of geoscientists now reports that such a rapid climate change occurred in different regions with a time difference ...

LAST 30 PRESS RELEASES:

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital

New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment

New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment

Pennington Biomedical’s Dr. Steven Heymsfield named LSU Boyd Professor – LSU’s highest faculty honor

Study prompts new theory of human-machine communication

New method calculates rate of gene expression to understand cell fate

Researchers quantify rate of essential evolutionary process in the ocean

Innovation Crossroads companies join forces, awarded U.S. Air Force contract

Using new blood biomarkers, USC researchers find Alzheimer’s disease trial eligibility differs among various populations

Pioneering advances in in vivo CAR T cell production

Natural medicines target tumor vascular microenvironment to inhibit cancer growth

Coral-inspired pill offers a new window into the hidden world of the gut

nTIDE September2025 Jobs Report: Employment for people with disabilities surpasses prior high

When getting a job makes you go hungry

Good vibrations could revolutionize assisted reproductive technology

More scrutiny of domestic fishing fleets at ports could help deter illegal fishing

Scientists transform plastic waste into efficient CO2 capture materials

Discovery of North America’s role in Asia’s monsoons offers new insights into climate change

MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies

Researchers discover massive geo-hydrogen source to the west of the Mussau Trench

Even untouched ecosystems are losing insects at alarming rates, new study finds

Adaptive visible-infrared camouflage with wide-range radiation control for extreme ambient temperatures

MD Anderson research highlights for September 5, 2025

Physicists create a new kind of time crystal that humans can actually see

Reminder: Final media invitation for EPSC-DPS2025 and details of media briefings on RAMSES and Juno missions

[Press-News.org] Prostate cancer stem cells are a moving target, UCLA researchers say